Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo, France/Belgium Lymphoma Group to Collaborate on Valemetostat Trial
February 26, 2021
- MSD’s 9-Valent HPV Vaccine Now Available in Japan
February 25, 2021
- Ken Takeshita to Become Daiichi Sankyo’s Global R&D Head in April
February 25, 2021
- Takeda Launches Japan PI/II Trial of Novavax COVID-19 Vaccine
February 25, 2021
- Japan Pharma Market Shrinks 2.4% on COVID-19, Price Cuts: IQVIA
February 24, 2021
- Taiho’s HSP90 Inhibitor Extends PFS in GIST
February 24, 2021
- Lusefi’s OD Film Version Filed in Japan: Taisho
February 24, 2021
- Astellas’ Hot Flash Drug Hits Primary Goals in PIII Studies
February 22, 2021
- Astellas/Seagen Seek Padcev’s Full Approval, Label Expansion in US
February 22, 2021
- Chugai to Develop Atea’s COVID-19 Drug AT-527 in Japan
February 22, 2021
- Japan-Bound Flights for COVID-19 Vaccines Get Underway: Pfizer, DHL, ANA
February 22, 2021
- Mitsubishi Tanabe, Keio University Tie Up for Research of Neutralizing Antibodies for COVID-19
February 22, 2021
- Ono Sets Up Investigation Panel on Bribery Issue
February 19, 2021
- Kyowa Kirin’s Novel Antibody Hits Primary Goal in Global PII for Atopic Dermatitis
February 19, 2021
- Ono Files Opdivo for Adjuvant Therapy for Esophageal Cancer in Japan
February 19, 2021
- Chugai Re-Files Patent Suit over Edirol, Now Focuses on Crystalline Form
February 18, 2021
- Mitsubishi Tanabe Accelerating Drug Discovery via Open Innovation, Early-Stage Data Sharing
February 18, 2021
- Novo Training Its Sights on Oral Diabetes Market with Rybelsus, Not Switches from GLP-1 Injectables
February 17, 2021
- FoundationOne Approved as a CDx for Pemigatinib: Chugai
February 17, 2021
- Shionogi Pharma Set to Expand CDMO Biz with Continuous Manufacturing, Eyes 10 Billion Yen Sales in FY2024
February 17, 2021
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…